Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2020

01-07-2020 | Obesity | Epidemiology

Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features

Authors: Suélène Georgina Dofara, Sue-Ling Chang, Caroline Diorio

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Login to get access

Abstract

Background

Matrix metalloproteinases (MMP)-2 and -9 may play an important role in adipogenesis and carcinogenesis. We investigated whether some polymorphisms located in these genes are associated with body adiposity and mammographic breast density, which are risk factors for breast cancer.

Methods

Our study population included 731 premenopausal women. Multivariate generalized linear models were used to evaluate the association of polymorphisms rs243865 in MMP-2 and rs3918242, rs17576, rs2250889 and rs2274756 in MMP-9 with anthropometric factors that refer to adiposity and mammographic features (percent density, dense area and non-dense area) measured by computer-assisted method.

Results

The number of copies of rs243865 T allele in MMP-2 was associated with increased means of anthropometric factors (ptrend < 0.05 for all except waist-to-hip ratio). The same allele of rs243865 was associated with decreased mean percent density (ptrend = 0.036) and increased mean non-dense area (ptrend = 0.031) when adjusted for potential confounders, but these associations were attenuated when further adjusted for adiposity.

Conclusion

These findings suggest that the relation between rs243865 in MMP-2 and mammographic features could be mediated by adiposity.
Literature
1.
Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRef
2.
Manicone AM, McGuire JK (2008) Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19(1):34–41CrossRefPubMed
3.
4.
Bouloumié A et al (2001) Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50(9):2080–2086PubMedCrossRef
5.
Derosa G et al (2008) Matrix metalloproteinase-2 and-9 levels in obese patients. Endothelium 15(4):219–224PubMedCrossRef
6.
Belo VA et al (2009) Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42(10–11):984–990PubMedCrossRef
7.
Andrade VL et al (2012) Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clin Biochem 45(6):412–415PubMedCrossRef
8.
9.
Belo VA et al (2013) Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep 40(3):2697–2704PubMedCrossRef
10.
Andrade VL et al (2012) Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity. DNA Cell Biol 31(6):1054–1057PubMedCrossRef
11.
Belo V et al (2012) Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes 36(1):69CrossRef
12.
13.
O’Reilly MS et al (1999) Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274(41):29568–29571PubMedCrossRef
14.
15.
Paszek MJ, Weaver VM (2004) The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 9(4):325–342PubMedCrossRef
16.
17.
Somiari SB et al (2006) Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 119(6):1403–1411PubMedCrossRef
18.
Wu ZS et al (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122(9):2050–2056PubMedCrossRef
19.
Patel S et al (2011) Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression. Clin Biochem 44(10–11):869–872PubMedCrossRef
20.
Somiari SB et al (2006) Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 233(1):98–107PubMedCrossRef
21.
22.
Sheen-Chen S-M et al (2001) Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 173(1):79–82PubMedCrossRef
23.
Zhou Y et al (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25(3):399–404PubMedCrossRef
24.
Néjima DB et al (2015) Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study. Tumor Biol 36(5):3815–3822CrossRef
25.
Delgado-Enciso I et al (2008) Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Investig 65(1):68–72CrossRef
26.
Saeed HM et al (2013) Matrix metalloproteinase-2 C (-1306) T promoter polymorphism and breast cancer risk in the Saudi population. Acta Biochim Pol 60(3):405–409PubMedCrossRef
27.
Lei H et al (2007) Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103(1):61–69PubMedCrossRef
28.
Roehe AV et al (2007) Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 102(1):123–124PubMedCrossRef
29.
Beeghly-Fadiel A et al (2009) Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Prev Biomarkers 18(6):1770–1776CrossRef
30.
Zagouri F et al (2013) MMP-2 −1306C%3eT polymorphism in breast cancer: a case–control study in a South European population. Mol Biol Reports 40(8):5035–5040CrossRef
31.
Slattery ML et al (2013) Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS ONE 8(5):e63165PubMedPubMedCentralCrossRef
32.
Beeghly-Fadiel A et al (2011) MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Res Treat 126(2):507–513PubMedCrossRef
33.
34.
Chahil JK et al (2015) Genetic polymorphisms associated with breast cancer in Malaysian cohort. Indian J Clin Biochem 30(2):134–139PubMedCrossRef
35.
Rahimi Z, Yari K, Rahimi Z (2015) Matrix metalloproteinase-9-1562T allele and its combination with MMP-2-735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev 16(3):1175–1179PubMedCrossRef
36.
Huo C et al (2014) Mammographic density—a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 144(3):479–502PubMedCrossRef
37.
38.
39.
Diorio C et al (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Prev Biomarkers 14(5):1065–1073CrossRef
40.
Diorio C et al (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Prev Biomarkers 17(4):880–888CrossRef
41.
Habel AF et al (2019) Common matrix metalloproteinase-2 gene variants and altered susceptibility to breast cancer and associated features in Tunisian women. Tumor Biol 41(4):1010428319845749CrossRef
42.
Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573PubMedCrossRef
43.
Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene role of sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549–7558PubMedCrossRef
44.
Chiranjeevi P et al (2014) Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer. Tumor Biol 35(2):1351–1356CrossRef
45.
Hovhannisyan G et al (2009) Differences in measured mammographic density in the menstrual cycle. Cancer Epidemiol Prev Biomarkers 18(7):1993–1999CrossRef
46.
Zhang B et al (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99(14):1788–1794PubMedCrossRef
47.
Tesfaigzi Y et al (2006) Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. Int J Chronic Obstruct Pulm Dis 1(3):267
Metadata
Title
Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features
Authors
Suélène Georgina Dofara
Sue-Ling Chang
Caroline Diorio
Publication date
01-07-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05651-0

Other articles of this Issue 1/2020

Breast Cancer Research and Treatment 1/2020 Go to the issue

Epidemiology

Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study

Clinical trial

ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer

Clinical trial

HER2-targeted therapy influences CTC status in metastatic breast cancer

Clinical trial

The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer

Epidemiology

Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology

Epidemiology

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits